The ninth Annual General Meeting of the British Society for Antimicrobial Chemotherapy (incorporated) will be held 12.30pm Tuesday 20 March 2012 Wolkson Theatre, Royal College of Physicians, London

CONTENTS

Agenda 2-3
Unconfirmed minutes of the Annual General Meeting 2011 4-7

Open to all Members of the BSAC
Voting rights limited to Ordinary and Honorary Members of the Society

Matthew Dryden, General Secretary
AGENDA

The next Annual General Meeting of the British Society for Antimicrobial Chemotherapy will be held at 12.30pm on Tuesday 20 March 2012, Royal College of Physicians of London, London

Distribution: All BSAC Ordinary and Honorary Members

1 Apologies for absence
2 To receive the minutes of the 2011 Annual General Meeting
3 President’s report
4 Elections

To note in accordance with Articles 47-63, the election of:

a Dr Matthew Dryden to serve a 2nd and final term of office as General Secretary 2012-2015
b Dr Ian Morrissey to serve a 2nd and final term of office as Grants Secretary 2012-2015
c Ordinary Members of Council to serve 2012-2015

de and in accordance with Article 7, the names of those elected to Ordinary Membership of the Society:

Mrs Gemma Lasseter, Project Manager, Gloucester Royal Hospital, Gloucester; Dr Deborah Modha, Consultant Microbiologist, Leicester Royal Infirmary, Leicester; Dr David Wareham, Senior Lecturer/Consultant, Queen Mary/Barts & The London, London; Dr Diane Ashiru-Oredope, Pharmacist Lead, Health Protection Agency, London; Miss Laura Evans, Doctoral Researcher, University of Birmingham, Birmingham; Dr Richard Harvey, Lecturer, Dept of Pharmacy, King’s College London; Mr Jonathan Urch, Lead Pharmacist-Anti Infectives, Southmead Hospital, Bristol; Dr Manyando Milupi, Consultant Microbiologist, Doncaster Royal Infirmary, Doncaster; Miss Katherine Henderson, Scientist (Epidemiology), Health Protection Agency, London; Miss Ruth Blackburn, Information Analyst, Health Protection Agency, London; Dr Berit Muller-Pebody, SEN Scientist, Health Protection Agency, London; Dr Jorge Cepeda, Consultant Microbiologist, Basingstoke Hospital, Basingstoke; Mrs Ruth Hay, Senior BMS, Spire Hospital Little Aston, Sutton Coldfield; Ms Kelly Alexander, Lead Pharmacist Antibiotics, Manchester Royal Infirmary, Manchester; Dr Ken Agwu, Consultant Microbiologist, Doncaster Royal Infirmary, Doncaster; Miss Kirsty Skinner, PhD Student, Glasgow Caledonian University, Glasgow; Mr Jaroslav Boberek, PhD Student, The Royal Veterinary College, London; Mrs Susan Hawkey, Director, Modus Medica Ltd, Gloucestershire; Dr Krishna Banavathi, Consultant Microbiologist, University Hospital of North Staffordshire, Stoke on Trent; Miss Meredith Hawking, e-Bug Project Assistant, Health Protection Agency, Gloucester; Dr Donna Lecky, e-Bug Project Manager, Health Protection Agency, Gloucester; Mr Andrew Karvot, Consultant Pharmacist, Diana Princess of Wales Hospital, Grimsby; Mrs Natalie Parker, Antimicrobial Pharmacist, Royal Hampshire County Hospital, Winchester; Miss Alison Orr, Antimicrobial Pharmacist, City General Hospital, Stoke on Trent; Miss Natalya Doroshenko, PhD student, School of Engineering Sciences, University of Southampton, Southampton; Miss Amelia Lawler, Research Technician, School of Immunity and Infection, University of Birmingham, Birmingham; Mrs Katherine Oates, Antimicrobial Pharmacist, Duchess of Chester NHS Foundation Trust, Chester; Miss Corrine Whittingham, Senior Pharmacist - Antimicrobials, Leicester Royal Infirmary, Leicester; Mr Khaled Alshamaki, PhD Student, Health & Wellbeing Dept, Sheffield Hallam University, Sheffield; Dr Dorina Timofte, Research Associate, School of Veterinary Science, University of Liverpool, Liverpool; Mr Jonathan Lewis, Laboratory Manager, Gloucestershire Royal Hospital, Gloucester; Ms Catherine Ludden, PhD Student, Dept of Bacteriology, National University of Ireland, Galway; Dr Elizabeth O’Gara, Senior Lecturer, School of Applied Sciences, University of Wolverhampton, Wolverhampton; Dr Alice Wort, ST Microbiology Trainee, Freeman Hospital, Newcastle Upon Tyne; Miss Grace Richmond, Res Technician, School of Immunity & Infection, University of Birmingham, Birmingham; Mr David Sharpe, Antimicrobial Pharmacist, Alder Hey Children's Hospital, Liverpool; Miss Anli Yue Zhou, 4th year Medical Student, University hospital of South Manchester; Mr Barry Mather, Biomedical Scientist, Whiston Hospital, Prescot; Miss Lindsey Smith, Biomedical Scientist, Whiston Hospital, Prescot; Dr Rishi Dhillon, SpR Microbiology & Virology, Chelsea & Westminster Hospital, London; Mr Chris Waghorn, Product Manager, Launch Diagnostics, Longfield; Dr Anne Barnard, Research Scientist, Phicotherapeutics Ltd, Babraham, Cambridge; Dr Katy Pitts, Research Scientist, Phicotherapeutics Ltd, Babraham,
Cambridge; Dr Emmanuele Severi, Research Scientist, Phicotherapeutics Ltd, Babraham, Cambridge; Dr Hongmei Wang, Research Scientist, Phicotherapeutics Ltd, Babraham, Cambridge; Dr Gloria Kiapi, Medical Microbiology Registrar, Queen Elizabeth Hospital, Woolwich, London; Mr Liam Burke, PhD Student, Royal College of Surgeons in Ireland, Dublin; Dr Michael Allen, Senior Medical Development Advisor, Novartis Pharmaceuticals UK Ltd, Camberley; Mr Sydney Dias, BMS2, Hemel Hempstead General Hospital, Hemel Hempstead; Dr Eleanor Woodward, Research Scientist, Medical Microbiology, Southmead Hospital, Bristol; Miss Elena Domenech, Research Scientist, Southmead Hospital, Bristol; Dr Huw Williams, Reader in Microbiology, Department of Life Sciences, Imperial College London; Dr Jennifer Short, Consultant, Infectious Diseases, Heartlands Hospital, Birmingham; Dr Younis Dahar, Specialty Registrar, Addenbrookes Hospital, Cambridge; Mrs Parmjit Kaur Kang, Antimicrobial Pharmacist, New Cross Hospital, Wolverhampton; Dr Dalia Atallah, Head of Clinical Microbiology Laboratory and Head of Infection Control, Saudi Arabia; Mrs Pegah Hafezi, Senior Biomedical Scientist, Southmead Hospital, Bristol; Dr Joanna Macve, ST2 Microbiology, New Cross Hospital, Wolverhampton; Dr Erkal Ozkan, Medical Doctor, USAK State Hospital, Turkey; Dr Sarah Whitehead, Consultant Microbiologist, Southern General Hospital, Glasgow; Dr Ursula Theuretzbacher, Founder, Center for Anti-Infective Agents, Vienna, Austria; Mrs Samim Patel, Pharmacist: Antimicrobial Lead, Bolton Hospitals NHS Trust, Bolton; Mr Afzal Jafrani, Reasearch in Development of Antimicrobials in human medicine - Retired, Karachi, Pakistan; Dr Ana Filipa Frutuoso Mendes Henrques, Post Doctoral Researcher, University of Minho, Braga, Potugal; Dr Jim Wade, Consultant Microbiologist, Kings College Hospital, London; Dr Kirthiga Sithamparanathan, Medical Microbiology – ST4, NBT NHS, Bristol; Miss Anuforom Olachi, PHD Student, University of Birmingham; Dr Andrew Hall, Research Fellow, University of Aberdeen; Dr Josephine Effick, Doctor, St Georges Hospital, Tooting; Dr Naomi Maree Fleming, Antibiotic Pharmacist, Community Health Services, Milton Keynes; Mrs Netta Tyler, Antimicrobial Pharmacist, Papworth Hospital NHS Trust, Cambridge; Miss Elizabeth Doford-Hook, Medical Student, University of Leeds; Professor Stephen H Gillespie, Professor of medicine, University of St Andrews; Dr Hala MW Kandil, Consultant Microbiology, Royal Free Hampstead NHS Trust; Dr Giancarlo Biagini, Reader, Liverpool School of Tropical Medicine; Dr Bolhuis, Senior Lecturer in Microbiology, University of Bath; Dr Haselgrave, Research Associate, University of Leicester; Dr Darley, Consultant Medical Microbiologist, North Bristol NHS Trust; Dr Kustos, Microbiology Consultant, Countess of Chester; Mr Readwin, Biomedical Scientist, St Thomas’ Hospital; Ms Archyangelio, Matron Infection Control, City Hospitals Sunderland; Miss Ciesiezczuk, PhD Student, Queen Mary’s University of London; Dr Laundy, Consultant Microbiologist, St Georges Hospital; Mr Keith-Welsh, Pharmacy Project Lead, ICNET International; Dr Nwawu, Research Associate, University of Nottingham; Dr Kapati, Research Scientist, HPA Birmingham; Dr Haydon, Director of Research, Biota Europe LTD; Dr Drew, Consultant Microbiologist, Alder Hey Children’s; Mr Kealy, Super intendent Pharmacist, Medicines2You LTD; Mr Wade, Consultant Pharmacist (ID), Guy’s & Thomas’ NHS Foundation Trust; Dr Goel, Consultant Microbiologist, Frimley Park Hospital; Mr Tucker, Specialist Biomedical Scientist, Poole General Hospital; Dr Schneiders, Lecturer in Molecular Bateriology, Queen's University Belfast; Dr Keane, Medical Director, TCP Homecare, Dublin; Miss Mohammadi, Lead Antibiotic Pharmacist, Lewisham Healthcare NHS Trust; Dr Wyllie, Consultant Microbiologist, Queen Alexandra Hospital, Portsmouth; Dr Bush, Professor, Indiana University, USA; Dr Hanulik, Consultant Microbiologist, University Hospital Olomouc, CZ; Professor Thomas, Professor of Molecular Genetics/Director of Graduate Research College of Life & Enviromental Sciences, University of Birmingham

5 Financial Report

To:

a receive the report of the Honorary Treasurer

b receive and approve the company accounts for the period 1 January – 31 December 2010

c note the appointment of Chantrey Vellacott, DFK, London as the Society’s auditors for the period 1 January – 31 December 2012

6 Editor in Chief’s report

7 To receive the Trustees report (including reports on meetings, education & grants)

8 Date, time and place of the next meeting

9 Any other business
The unconfirmed minutes of the Annual General Meeting held 23 March 2011, at the International Convention Centre, Birmingham

47 Ordinary and Honorary Members of the Society were present. Professor Laura Piddock, President, resided.

1 Chairman’s welcome and apologies for absence

The Chairman welcomed members to the meeting. Apologies for absence were noted.

2 Minutes of the 2011 AGM

The unconfirmed minutes of the Annual General Meeting held on 23 March 2011 were RECEIVED and signed as a true record.

3 President’s report

The President, Professor Laura Piddock reported that the Society had enjoyed a busy year in 2010, with activities continuing to operate on many fronts, in particular education and meetings, funding, quality improvement and on-going national programmes of resistance surveillance and susceptibility testing.

Those present heard that a year ago the President had reported on two new initiatives - the Outpatient Parenteral Antimicrobial Prescribing (OPAT) initiative led by Professor Dilip Nathwani that supports, guides and encourages the establishment of standardized OPAT services throughout the UK wherever the clinical need may exist and The Urgent Need Working Party - Regeneration of Antibacterial Drug Discovery and Development under the chairmanship of Professor Richard Wise. She was pleased to report excellent progress on both fronts.

The OPAT project led to BSAC hosting highly successful meeting in February, attended by over 300 participants from more than 10 disciplines. This is the beginning of an initiative which will see publication of the good practice recommendations, development of an online business toolkit, national database, the outputs of which will be published on a national outcomes registry.

The Urgent Need Initiative has produced its report which is the basis from which the Society will engage with patient charities, regulators, government and industry to push forward and promote the need to mobilise action necessary to regenerate the antibiotic pipeline.

The President reported that Council remains very aware of the need to engage effectively with all audiences, and during 2010 redeveloped and re-launched its website. The site is much improved, and now includes webcasts of BSAC events, improved resources and provides a much sharper public image than the previous site. One downside was that the new technology cannot support a long standing resource on hospital acquired infection which was developed by BSAC a decade ago. It has been agreed that this will be redeveloped in 2011.

The assembly noted that as in previous years BSAC continued to develop and deliver high quality meetings and educational events for professionals with an interest in, antimicrobial chemotherapy and infection management. Over 24 events were organised in 2010 including the UK Infection Collaborative Quality Improvement Workshop, the 2010 Spring Meeting on Difficult to Treat Infections, 10 regional workshops on Travel Related Infections, the 5th Antibiotic Resistance Mechanisms: Workshop for Researchers, a pneumonia conference tour and many more! BSAC also joined with veterinary colleagues to co-present a one-day symposium at the annual Veterinary Laboratory Agency – the meeting was very well attended and received and we will be repeating this at some point in the future.

Once again the Society supported national programmes of resistance surveillance, the results of which are published on a dedicated website. Both the respiratory and bacteraemia programmes are organised under contract with industry, to whom BSAC is grateful for their continued support in this important area. BSAC also continues to underwrite the full costs of development of the standardised methodology for susceptibility testing and again held a user group day and 2 residential workshops during 2010. This present joined the President in thanking Dr Rosy Reynolds and Mrs Jenny Andrews for their expert management of these important activities on BSAC’s behalf.
The Assembly noted that the BSAC Grants Programme remained popular with members and non-members alike, and details of grants awarded in 2010, and previous years, are now published on the BSAC website. 2010 also saw a high influx of grant applications for grants to be awarded in 2011, this included applications for the 2nd BSAC PhD Studentship that will be awarded in 2011. All concurred that this relatively new award makes an important contribution to academic microbiology in the UK.

The President reported on working party activities during 2010, asking the assembly to note that a number of working parties were in session during 2010 developing new, or reviewing existing guidelines that will lead to publication on topics such as therapeutic drug monitoring, endocarditis, appropriate antibiotic prescribing and standards for outpatient parenteral antimicrobial therapy. Guideline development remains an important part of our agenda which we know is much valued by the Membership.

In closing the President acknowledged the support the Society receives from the Department of Health and industry who provide unrestricted educational grants and sponsorship to support educational activities and meetings.

4 Elections

In accordance with Articles 47 – 63, the election of the following Officers, Ordinary Members of Council and Ordinary Member of the Society was noted:

(a) Dr Nicholas Brown to serve as:
   Vice President Elect 2011-2012
   President 2012-2015
   Vice President Past President 2015-2017

(b) Dr Conor Jamieson to serve as Honorary Treasurer Elect 2011-2012 and Honorary Treasurer 2012-2015

(c) Professor Peter Davey to serve as Education Secretary 2011-2014

(d) Articles 47 – 53, the election of Drs Andrew Stacey and Frances Burke to serve as Ordinary Members of Council 2008-2011

(e) Article 7, the names of those elected to Ordinary Membership of the Society:

Dr Jose Antonio Ainsa, Lecturer on Microbiology, Universidad de Zaragoza, Spain; Dr Sani Aliyu, Consultant in Microbiology & ID, Addenbrookes Hospital, Cambridge; Mrs Fatmah Alasmasy, PhD student, University of Bradford, Bradford; Dr Sally Anne Argyle, Lecturer (Veterinary Clinical Studies), University of Edinburgh, Edinburgh; Mr Jeff Aston, Antibiotic Pharmacist, Birmingham Children's Hospital, Birmingham; Dr Isabel Baker, Specialist Registrar, Southmead Hospital, Bristol; Dr Reena Bambini, Specialist Registrar, Sheffield Teaching Hospital NHS Trust, Sheffield; Dr Bassam Ben-Ismaeil, Consultant Microbiologist, Singleton Hospital, Swansea; Dr Frances Burke, Senior Fermentation Scientist, Eli Lilly & Company Ltd, Liverpool; Mrs Kam Cheema, Principal Pharmacist, Ealing Hospital, Southall; Miss Georgina Cox, PhD student, University of Leeds, Leeds; Mr Jonathan Curry, PhD Student, University of London, London; Miss Victoria Elizabeth Daniel, Biomedical Scientist, University Hospital of Wales, Cardiff; Dr Farnaz Dashti, Locum Microbiologist, London; Dr David Farren Speciality Registrar in Medical Microbiology, The Royal Hospital, Belfast; Dr Sarah Furrows, Consultant Microbiologist, Kingston Hospital, Kingston-upon-Thames; Ms Daniela Goncalves PhD Student, ISAVE Instituto Superior de Saude, Portugal; Dr Abdul Ghafrur, Consultant in Infectious Diseases, Apollo Speciality Hospital, India; Mr Mark Gilchrist, Lead Pharmacist ID, Imperial College, London; Dr Simon Goldenberg, Clinical Research Fellow, St Thomas’ Hospital, London; Dr Rupert Handy, Consultant Physician Infectious Diseases, Auckland City Hospital, New Zealand; Miss Katie Hatton, Specialist Pharmacist Antimicrobials, Chelsea and Westminster Hospital, London; Dr Lauren Heath, STI Medical Microbiology, Leeds General Infirmary, Leeds; Dr Hong-Xia Jiang, South China Agricultural University, College of Veterinary Medicine, China; Dr Lim Jones, ST3 Medical Microbiology, University Hospital of Wales, Wales; Dr Prasanna Kumbri, Consultant Microbiologist, The Hillingdon Hospital, Uxbridge; Dr Nitish Khanna, Specialist Registrar Microbiology, Glasgow Royal Infirmary, Glasgow; Dr Tana Laznickova, Consultant Microbiologist, Queens Hospital, Burton on Trent; Miss Nicola Lewis, Lead Antimicrobial Pharmacist, Guildford; Dr Christopher Longshaw, Scientific Advisor, Wyeth Pharmaceuticals, Maidenhead; Miss Tracy Lyons, Lead Pharmacist-Microbiology, St Mary’s Hospital, London; Miss Katherine Mariner, PhD student, University of Leeds, Leeds; Dr Li Mcrae, Clinical Scientist, Health Protection Agency, Birmingham; Dr Aaron Nagar, Medical Microbiology & Virology STR1, Royal Belfast Hospital, Belfast; Miss Nicola Ooi, PhD student, University of Leeds, Leeds; Miss Linda Oyama, Postgraduate Student, University of Leeds, Leeds; Mrs Rakhee Patel, Antimicrobial/Surgical Pharmacist, Darent Valley Hospital, Dartford; Dr Lorraine Power, Microbiology Consultant, Limerick Regional Hospital; Dr Arthur Pranada, Intern/Junior Doctor, Dortmund, Germany; Dr Paul Race, Research Fellow, University of Bristol, Bristol; Dr Rajesh Rajendran, Specialist Registrar, Belfast City Hospital, Belfast; Mr Christopher Randall, PhD student, University of Leeds; Dr Essam Rizkalla, Consultant Microbiologist,
5 Financial Report

The Annual General Meeting RECEIVED the report of the Honorary Treasurer, including the audited accounts for the period 1 January – 31 December 2009. It was noted that accounts are prepared under, and comply with the Statement of Recommended Practice on Accounting by Charities issued in 2005. The accounts are expressed in terms of income and expenditure for the 3 main ways in which BSAC meets its charitable objectives – through research, education and communication. The notes to the accounts detail how the costs are allocated across these headings.

The Treasurer was both pleased and relieved to report that 2010 was on the whole much more positive that the previous year. The stock market showed some recovery and the value of the Society’s investments improved markedly helping to ensure that the society remains financially sound.

The assembly noted that as for previous years we continued to operate an annual budgeting and planning process, which was overseen and approved by Council.

The Society’s principal sources of funding were income from the Journal of Antimicrobial Chemotherapy, Membership Subscriptions and revenue from meetings activities in the form of delegate registration fees and unrestricted educational grants from Industry. As planned, Council had spent £261,953 from the designated funds, the majority of which was expended on the Society’s grants programme. Members noted that the general fund is largely represented by the investment portfolio, which performed well in a difficult market during 2009 with realised and unrealised gains of £640,661. The Trustees intend to retain the investment portfolio to generate income that will support the long-term fulfilment of the Society’s charitable objectives. To ensure funds are dispersed in furtherance of BSAC’s aims the Society holds designated funds for grant, education and meeting activities. Further, the Society has a restricted fund through which it supports the national programme of resistance surveillance.

Dr Logan reported that despite the continued challenged financial climate BSAC’s investment company Rathbones had still managed the spread of the portfolio to ensure income from investments remained close to the target set by Council (£80,000 per annum). A balanced investment portfolio is maintained and the investment advisers have been charged with increasing income from investments whilst protecting the capital value of the fund, this being the policy position of Council agreed in 2004 and reviewed and endorsed in 2009. The assembly was asked to note that the Society has placed certain restrictions on the way in which the fund is managed, including precluding investments in named pharmaceutical companies to ensure conflicts of interest, perceived or real, do not arise.

As prescribed by the Charity Commission, Council remains mindful of the need to ensure funds are dispersed in furtherance of its aims through its charitable activities and in 2010 BSAC maintained the range of designated funds that now include education and meeting activities in addition to grants. The Society also continued to operate a restricted fund through which the national programme of resistance surveillance is supported.

The Treasurer reported that the premises at 11 The Wharf now form part of the Society investment portfolio. Development plans for the site were put on hold at the end of 2008, and despite indications that redevelopment proposals are back on track we have not received a firm offer of an option lease agreement or purchase price for the property. The building is being marketed by 2 agents and our aim is to secure a rental on the entire premises. We have had several companies interested but no firm offer to date.

The assembly noted that the Trustees’ policy is to maintain a level of free reserves equivalent to not less than 24 months expenditure, and aim to have a reserve for 36 months expenditure. This policy would enable the Society to remain operational for between 24-36 months (estimated at £3 million against total free reserves of £2.6 million) and fulfil its commitments in terms of grants, education and meetings activities, some of which are subject to a 3-year planning / completion cycle.
In closing the Treasurer added her thanks to those of the President to those companies and organisations who generously provided unrestricted educational grants, gifts in kind and sponsorship that enabled the Society to deliver educational benefits to its Membership and the wider antimicrobial community during the past year.

The Annual General Meeting:

(a) Received and approved the company accounts for the period 1 January – 31 December 2010.

(b) Noted and approved the appointment of Chantrey Vellacott, DFK, London as the Society’s auditors for the period 1 January – 31 December 2011.

6 Editor in Chief’s report

The Annual General Meeting received the report of the Editor-in-Chief, the detail of which was published in the Trustees report.

7 Trustees report

The Annual General Meeting received the Trustees Report that included written reports on grants, education and meetings activities, in addition to all other society matters transacted

8 Date, time and place of the next meeting

To be announced.

9 Any other business

There being no other business, the meeting was declared closed.